John J. Alam, MD is CEO of CervoMed Inc. (until August 2023 known as EIP Pharma), a clinical-stage biotechnology company advancing CNS-focused therapeutics to benefit patients with degenerative diseases of the brain. Until May 2014, he was therapeutic area head for diseases of aging, including Alzheimer’s and Parkinson’s disease, within Sanofi R&D. Previously, from 1997 until 2008 he held positions of increasingly responsibility at Vertex Pharmaceuticals, including Chief Medical Officer and EVP, Medicines Development. And, from 1991 to 1997, while at Biogen, Inc, he led the clinical development of Avonex (interferon beta-1a) for the treatment of multiple sclerosis. John received a S.B. in chemical engineering from the Massachusetts Institute of Technology and a M.D. from Northwestern University School of Medicine. Subsequently, he completed an internal medicine residency at Brigham and Women’s Hospital and a post-doc at Dana-Farber Cancer Institute.